

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
22 March 2012 (22.03.2012)

PCT

(10) International Publication Number
WO 2012/037499 A1

(51) International Patent Classification:

A61K 31/4174 (2006.01) **A61P 27/06** (2006.01)
C07D 233/64 (2006.01) **A61P 17/04** (2006.01)

(21) International Application Number:

PCT/US2011/052004

(22) International Filing Date:

16 September 2011 (16.09.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/383,370 16 September 2010 (16.09.2010) US

(71) Applicant (for all designated States except US): **ALLERGAN, INC.** [US/US]; 2525 Dupont Drive, Irvine, California 92886 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **CHOW, Ken** [US/US]; 20 Tidal Surf, Newport Coast, California 92657 (US). **DIBAS, Mohammed, I.** [US/US]; 28871 Niguel Vista, Laguna Niguel, California 92677 (US). **DONELLO, John, E.** [US/US]; 34041 Pequito Drive, Dana Point, California 92629 (US). **GARST, Michael, E.** [US/US]; 2627 Raqueta Drive, Newport Beach, California 92660 (US). **GIL, Daniel, W.** [US/US]; 2541 Point Del Mar, Corona Del Mar, California 92625 (US). **WANG, Liming** [US/US]; 16 Trinity, Irvine, California 92612 (US).

(74) Agents: **ENE, Doina et al.**; Allergan, Inc., 2525 Dupont Drive, Irvine, California 92612 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))

(54) Title: ESTER PRO-DRUGS OF [3-(1-(1H-IMIDAZOL-4-YL)ETHYL)-2-METHYLPHENYL] METHANOL

(57) Abstract: The present invention relates to novel compounds, ester pro-drugs of [3-(1-(1H-imidazol-4-yl)ethyl)-2-methylphenyl] methanol, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals in the treatment of conditions mediated by adrenergic receptors.



WO 2012/037499 A1